Hyperlipoproteinemia Type IV

精彩内容日前，国家药监局官网显示，鲁南贝特制药的阿昔莫司胶囊一致性评价补充申请获批，成为该产品首家过评企业。米内网数据显示，阿昔莫司胶囊近年在中国公立医疗机构终端销售规模均超过1亿元，是血脂调节剂化药TOP18产品，鲁南贝特制药的市场份额最大。来源：米内网一致性评价进度数据库阿昔莫司胶囊可作为替代疗法或辅助疗法用于降低对其他治疗（如他汀类药物或贝特类药物）不能充分缓解的患者的甘油三酯水平，适用于高甘油三酯血症（Fredrickson IV型高脂蛋白血症）、高胆固醇和高甘油三酯血症（Fredrickson IIB型高脂蛋白血症）。2023年中国公立医疗机构终端血脂调节剂化药TOP20产品来源：米内网中国公立医疗机构药品终端竞争格局注：市场份额不足1%以*表示阿昔莫司胶囊近年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售规模均超过1亿元，是血脂调节剂化药TOP18产品，鲁南贝特制药的市场份额最大。米内网数据显示，阿昔莫司胶囊仅有3家企业拥有生产批文，鲁南贝特制药则是该产品首家过评企业，四川豪运药业的一致性评价补充申请在审，石家庄四药、北京福元医药等4家以仿制4类报产在审，获批后视同过评。鲁南贝特制药已过评心脑血管系统药物来源：米内网一致性评价进度数据库截至目前，鲁南贝特制药已有18款产品过评，心脑血管系统药物最多，有7款，其中，瑞舒伐他汀钙片在2023年中国公立医疗机构终端是20亿级别重磅品种，阿昔莫司胶囊、单硝酸异山梨酯片、盐酸索他洛尔片等3个品种为首家过评。据了解，鲁南贝特制药是鲁南制药集团控股子公司，生产西药片剂、注射液、缓释片、大输液、喷雾剂、胶囊剂、颗粒剂、滴眼剂等12个剂型，主要产品有鲁南欣康片、鲁南欣康缓释片、单硝酸异山梨酯注射液、奥美拉唑肠溶片、阿昔莫司胶囊、异氟烷麻醉剂等。资料来源：国家药监局官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons, and M&A since 2013. This influx of capital, combined with some critical scientific breakthroughs, has led to the approval of multiple drugs that are changing the lives of patients worldwide. We think this could be just the tip of the iceberg given that there are more than 1,000 clinical trials underway, preclinical companies are raising record-breaking capital and multiple academic labs are working on the latest iteration of the technology. Importantly, while the first few drugs were approved for rare diseases (such as spinal muscular atrophy, inherited retinal diseases, familial hypertriglyceridemia), we now have two COVID19 vaccines approved (mRNA based) and multiple drugs poised to be approved for more prevalent diseases in cardiology, neurology, oncology, and autoimmunity. Outside of COVID19, which is expected to generate $50b+ in revenue this year, we expect genetic medicine to top $20b in revenue by 2026.

Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons, and M&A since 2013. This influx of capital, combined with some critical scientific breakthroughs, has led to the approval of multiple drugs that are changing the lives of patients worldwide. We think this could be just the tip of the iceberg given that there are more than 1,000 clinical trials underway, preclinical companies are raising record-breaking capital and multiple academic labs are working on the latest iteration of the technology. Importantly, while the first few drugs were approved for rare diseases (such as spinal muscular atrophy, inherited retinal diseases, familial hypertriglyceridemia), we now have two COVID19 vaccines approved (mRNA based) and multiple drugs poised to be approved for more prevalent diseases in cardiology, neurology, oncology, and autoimmunity. Outside of COVID19, which is expected to generate $50b+ in revenue this year, we expect genetic medicine to top $20b in revenue by 2026.